Fennec Pharmaceuticals Inc (FENC)

[BioSpecialist]

Q-results out today ...

Burn-rate down to $400k Per Q / Cash untill year End means they have enough time after the 2x Phase 3 data to do a financing at much much higher Price if data is positive . A lottery ticket here that could make you rich .GLTA

Q-Results released today ..
http://finance.yahoo.com/news/adherex-provides-corporate-fiscal-ended-120000833.html

Cash and cash equivalents totaled $1.7 million at December 31, 2013

The two Phase 3 clinical trials studying Sodium Thiosulfate (STS) for prevention of hearing loss in children receiving cisplatin chemotherapy have progressed well. The US based Children Oncology Group (COG) ACCL0431 study completed enrollment in February 2012. Final data is expected to be released by COG during American Society of Clinical Oncology (ASCO) meeting in June 2014.

The enrollment of the European based SIOPEL 6 Study is almost complete, as 96 out of planned 102 patients have been randomized. The first three interim safety analyses were conducted after 20, 40 and 60 patients, and in each case, the Independent Data Monitoring Committee (IDMC) has recommended continuation of the study. An additional interim safety analysis for 80 patients is also expected to be performed shortly. Safety review data from this study have been submitted for presentation at ASCO in June 2014.

"We are encouraged by the recent strong patient participation in SIOPEL 6 and the continued recommendation by the IDMC that the study continue. In the event, that data from COG and SIOPEL show compelling results, Adherex plans to discuss the regulatory filing strategy for a New Drug Application (NDA) with the FDA during the second half of 2014" stated Mr. Rosty Raykov, Chief Executive Officer of Adherex.